Nonmelanoma Skin Cancer Risk Increased With Anti-TNF Use in RA
Researchers evaluated the risk for nonmelanoma skin cancer in patients receiving anti-tumor necrosis factor (TNF) inhibitors vs those who did not receive anti-TNFs.
Cancer
Risk for Infections and Cancer With Interleukin Treatment in Rheumatologic Diseases
Interleukin (IL) therapy for the treatment of rheumatologic diseases may increase the risk for serious infections, opportunistic infections, and cancer.
Interleukin Inhibitors Linked to Increased Infection, Cancer Risk in Rheumatologic Diseases
In patients with rheumatologic diseases, treatment with interleukin inhibitors may increase the risk of serious infections, opportunistic infections, and cancer, according to a systematic review and meta-analysis published in JAMA Network Open.
ASCO Releases Guideline on Addressing Osteoporosis Risk With Nonmetastatic Cancer
The guideline includes strategies to identify patients with nonmetastatic cancer who may be at a higher risk for osteoporotic fractures.
Increased Risk for Malignancy Found in Rheumatoid Arthritis
Compared with the general population, there is an increased risk for certain cancers in patients with rheumatoid arthritis (RA) in Singapore.
Lymphoma in Patients With Systemic Lupus Erythematosus: Expert Insights
In this expert interview, Sasha Bernatsky, MD, PhD, and Michelle Petri, MD, MPH, discuss the risk of non-Hodgkin lymphoma in SLE.
Thyroid Cancer Survivors Face Long-Term Osteoporosis and CVD Risks
Research shows that younger survivors are at increased risk of serious long-term health conditions resulting from thyroid cancer treatments.
Rituximab Decreases Malignancy Risk in ANCA-Associated Vasculitis
A retrospective analysis has shown that patients with ANCA-associated vasculitis treated with rituximab have a much lower risk of developing subsequent malignancies when compared with those treated with cyclophosphamide.
Next post in Vasculitis
